Cristina Tassorelli
Cristina Tassorelli
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial [0.03%]
用于治疗成人偏头痛的依非尼达与托吡酯的安全性、耐受性和疗效（TEMPLE）：一项随机对照 III 期试验
Uwe Reuter,Annelies Van Dycke,Jan Versijpt et al.
Uwe Reuter et al.
Background: Oral calcitonin gene-related peptide (CGRP) receptor antagonists such as atogepant have been approved for preventive treatment of migraine but have not been compared directly with conventional oral non-specifi...
Deep brain stimulation for the treatment of patients with dystonia: advances towards network-based personalised care [0.03%]
深部脑刺激治疗肌张力障碍患者：基于神经网络的个性化治疗的发展趋势
Anna Latorre,Kathryn J Peall,Andreas Horn et al.
Anna Latorre et al.
Dystonia is a complex movement disorder that can cause functional disability and reduce quality of life. Deep brain stimulation (DBS) provides meaningful benefits in patients with medically refractory dystonia, but clinical outcomes can var...
The role of the gut microbiome in mediating neuroinflammation in immune-based neurological disorders [0.03%]
肠道菌群在免疫介导的神经疾病中介导神经炎症的作用
Claude Steriade,Nicola Segata,Deepak Saxena
Claude Steriade
The gut microbiome can influence brain health by modulating neuroinflammation through various mechanisms, including immune regulation, the production of metabolites that affect neural function, gut and blood-brain barrier integrity, upstrea...
Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications [0.03%]
跨越不同谱系的帕金森病遗传学：具有转化意义的致病和风险变异的观察性基因组研究
Lara M Lange,Zih-Hua Fang,Mary B Makarious et al.
Lara M Lange et al.
Background: The genetic architecture of Parkinson's disease varies considerably across ancestries, yet most previous genetic studies have focused on individuals of European ancestry. We aimed to characterise the distribut...
Observational Study
The Lancet. Neurology. 2026 Aug;25(8):741-754. DOI:10.1016/S1474-4422(26)00198-5 2026
Survival estimates and their predictors in genetic frontotemporal dementia: an international, retrospective, cohort study [0.03%]
遗传性额颞叶痴呆的生存期估计及其预测因素：一项国际回顾队列研究
Arabella Bouzigues,Mario Grassi,Valentina Cantoni et al.
Arabella Bouzigues et al.
Background: What drives the heterogeneity of survival estimates in genetic frontotemporal dementia is unknown. We sought to understand the natural history and predictors of disease trajectory, which are crucial not only f...
Multicenter Study
The Lancet. Neurology. 2026 Aug;25(8):731-740. DOI:10.1016/S1474-4422(26)00197-3 2026
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial [0.03%]
帕金森病创新型药物 tavapadon(TEMPO-2)临床III期随机双盲对照试验：不同剂量的安全性，耐受性和疗效研究
Hubert H Fernandez,Perminder Bhatia,Leslie Cloud et al.
Hubert H Fernandez et al.
Background: Current dopaminergic therapies for Parkinson's disease carry significant limitations: levodopa can cause long-term motor complications, while D2/D3 receptor-targeting dopamine agonists can produce non-motor ad...
Clinical Trial
The Lancet. Neurology. 2026 Aug;25(8):721-730. DOI:10.1016/S1474-4422(26)00215-2 2026
Jules Morgan
Jules Morgan